Media store

Media Releases

Published on: 2 June 2020

FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® ...

Published on: 29 May 2020

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer

·Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy in ...

more

Published on: 29 May 2020

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa® (alectinib), ...
more

Upcoming Events
All

23July

Half year results 2020

(CEST)

Basel

15October

Third quarter sales 2020

(GMT)

Basel

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11

Share

Share via email

Share on Facebook

Share on Twitter

Share on LinkedIn

Share on Google+

Share on Xing

Close

© 2020 F. Hoffmann-La Roche Ltd

03.06.2020

Legal Statement

Privacy Policy

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

LinkedIn

Facebook

Pinterest

Twitter

YouTube